Genmab A/SGMABNASDAQ
Loading
Net Income ContractionContracting
Percentile Rank93
3Y CAGR+4.1%
5Y CAGR+5.2%
Studio
Year-over-Year Change

Total earnings after all expenses, taxes, and interest

3Y CAGR
+4.1%/yr
vs +38.7%/yr prior
5Y CAGR
+5.2%/yr
Consistent
Acceleration
-34.7pp
Decelerating
Percentile
P93
Near historical high
vs 5Y Ago
1.3x
Solid growth
Streak
1 yr
Consecutive declineContracting
PeriodValueYoY Change
2025$6.14B-21.7%
2024$7.84B+80.2%
2023$4.35B-20.2%
2022$5.45B+84.4%
2021$2.96B-37.9%
2020$4.76B+119.7%
2019$2.17B+47.1%
2018$1.47B+33.4%
2017$1.10B-7.0%
2016$1.19B-